ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
2.005
-0.025 (-1.23%)
May 18, 2026, 10:42 AM EDT - Market open
ALX Oncology Holdings Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, ALX Oncology Holdings stock has a consensus rating of "Strong Buy" and an average price target of $4.60. The average 1-year stock price forecast is 129.43% higher than the current stock price, while the lowest is $4.00 (+99.50%) and the highest is $6.00 (+199.25%).
Price Target: $4.60 (+129.43%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 19, 2026.
Analyst Ratings
The average analyst rating for ALX Oncology Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Initiates $5 | Buy | Initiates | $5 | +149.38% | Mar 19, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +99.50% | Mar 10, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $3 → $4 | Buy | Maintains | $3 → $4 | +99.50% | Feb 5, 2026 |
| UBS | UBS | Strong Buy Maintains $1.2 → $1 | Strong Buy | Maintains | $1.2 → $1 | -50.12% | May 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $2 | Strong Buy | Maintains | $5 → $2 | -0.25% | May 9, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.78
from -1.90
EPS Next Year
-0.71
from -0.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.68 | -0.57 | |||
| Avg | -0.78 | -0.71 | |||
| Low | -0.97 | -0.80 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.